Metformin tablets are taken by mouth with food to help control blood glucose in adults with type 2 diabetes. Metformin hydrochloride lowers glucose production in the liver and helps the body respond…
Metformin tablets are taken by mouth with food to help control blood glucose in adults with type 2 diabetes. Metformin hydrochloride lowers glucose production in the liver and helps the body respond better to insulin.
Metformin contains metformin hydrochloride, a biguanide used as a foundational treatment for type 2 diabetes. It is prescribed when the body does not use insulin efficiently or when the liver releases more glucose than the body needs. The aim is better blood-glucose control without directly stimulating the pancreas to release more insulin.
Metformin is supplied as tablets. The dose differs between strengths and between users, so there is no single amount that suits everyone.
Metformin is prescribed when the body does not use insulin efficiently or when the liver releases more glucose than the body needs. Metformin may be prescribed alongside insulin or a sulfonylurea when one treatment does not provide sufficient glucose control.
A prescriber should also assess:
Metformin may need to be temporarily withheld around certain contrast-enhanced scans, depending on kidney function and the type of examination.
The European Medicines Agency has published risk-minimisation information for metformin-containing medicines, including the importance of renal assessment and recognition of risk factors [2].
Reduced kidney function can allow metformin to accumulate and can increase the risk of lactic acidosis, a rare disorder in which lactic acid rises to dangerous levels.
Extra caution is required during situations that can reduce kidney function, such as:
Alcohol can increase the risk of lactic acidosis, especially when intake is heavy, sudden, or combined with poor nutrition or dehydration.
Metformin is most often associated with digestive side effects, especially during the first days or weeks of treatment or after a dose increase. These effects relate to the medicine’s action in the intestine and do not necessarily mean that treatment will be stopped permanently.
Common reactions include:
A metallic taste can appear unexpectedly. Food may taste slightly bitter or unusually sharp, and the symptom can be more noticeable in the morning. It often becomes less troublesome as treatment continues.
Diarrhoea can be inconvenient at work or during travel. Taking metformin with food, avoiding sudden dose changes, and maintaining fluid intake can help. Persistent diarrhoea deserves attention because dehydration can place additional stress on kidney function.
Many people tolerate metformin better when the starting dose is low and increased gradually. The prescribing clinician decides whether that approach is suitable. The FDA prescribing information describes gastrointestinal reactions as the most frequent adverse effects associated with metformin [1].
A rare but serious complication is lactic acidosis. Warning symptoms can include unusual weakness, severe tiredness, vomiting, abdominal pain, breathing difficulty, feeling cold, dizziness, or a slow or irregular heartbeat. These symptoms require urgent medical assessment, especially when several occur together.
Metformin hydrochloride reduces glucose production in the liver and helps the body respond more effectively to insulin. This improves the use of circulating glucose and supports better blood-glucose regulation without directly stimulating the pancreas to release more insulin.
Several practical errors can reduce tolerability or create avoidable risk:
Metformin is an oral, single-ingredient approach that improves insulin responsiveness and reduces glucose production in the liver, differing mechanistically from treatments that directly stimulate insulin release.
In clinical practice, doctors often view metformin as a long-term glucose-regulating treatment rather than a tablet that produces an immediate sensation. HbA1c results, fasting glucose, kidney function, weight, gastrointestinal tolerance, and adherence all help determine whether the plan is working.
A clinician will usually want to know about persistent diarrhoea, reduced appetite, dehydration, alcohol intake, and any new medicines. These details can change the safety assessment even when the metformin dose itself has stayed the same.
The main advantages are its established role in type 2 diabetes, low hypoglycaemia risk when used alone, and ability to improve insulin sensitivity. Limitations include gastrointestinal intolerance, the need to consider kidney function, possible vitamin B12 reduction, and the need for additional treatment when glucose targets are not reached.
Metformin used alone does not usually impair concentration or driving because it does not commonly cause hypoglycaemia. The risk changes when metformin is combined with insulin or a sulfonylurea, since those treatments can lower blood glucose. The European Medicines Agency information available from 2022 describes hypoglycaemia precautions in combination therapy. Do not drive or operate machinery when sweating, shaking, dizziness, blurred vision, confusion, or unusual weakness suggests low glucose.
Metformin may be prescribed for some adolescents with type 2 diabetes, but treatment in people under 18 requires an age-appropriate clinical assessment. It is not suitable to start solely on the basis of an adult’s dose or a relative’s treatment plan. NICE guidance from 2022 includes metformin within paediatric type 2 diabetes care under specialist management. Kidney function, growth, nutrition, and the cause of abnormal glucose levels all influence the decision.
Take the missed dose when remembered if the next scheduled dose is not soon. If the next dose is near, skip the missed dose and return to the usual schedule. Do not take two doses together to compensate, because this can increase gastrointestinal side effects. WHO diabetes medicine guidance published in 2023 supports avoiding unplanned dose doubling and maintaining a regular treatment routine.
Before starting, the prescriber should review kidney function, liver disease, dehydration risk, alcohol intake, pregnancy or breastfeeding, and medicines that may affect glucose or renal function. The clinician should also know about planned contrast-enhanced imaging and any previous metabolic acidosis. The FDA prescribing information for metformin, updated in 2022, emphasises renal assessment and risk-factor review before treatment. Long-term therapy may also require attention to vitamin B12, especially when symptoms or risk factors are present.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Long-term metformin use can lower vitamin B12 levels in some patients. Vitamin B12 is needed for red blood cell production and normal nerve function. A deficiency may develop gradually, so symptoms can be missed or attributed to diabetes itself.
Possible signs include:
A blood test can help identify low vitamin B12 or an emerging deficiency. People with anaemia, neuropathy, malabsorption, a vegetarian or vegan diet, or previous low B12 levels may need closer monitoring.
The UK Medicines and Healthcare products Regulatory Agency advises checking vitamin B12 in patients with symptoms or risk factors and considering periodic monitoring during long-term metformin therapy [3]. A low result can often be managed with vitamin B12 replacement while diabetes treatment continues, depending on the clinical assessment.
Metformin is not a substitute for a balanced diet. Regular meals containing appropriate sources of protein and micronutrients can support general health, while extreme calorie restriction may increase the risk of dehydration, weakness, and poor diabetes control.
Based on 4 reviews
James, 42 - no city, took metformin with his evening meal for several months. The first week brought loose stools and a metallic taste, but both settled after his routine became consistent. He said the medicine itself caused no noticeable low-glucose episodes.
Several months 10 Oct 2026Stephen L., 55 - no city, had started with a 500 mg tablet and noticed nausea when he took it before breakfast. Moving the dose to the meal, following his clinician’s plan, made the stomach discomfort less disruptive. He still found diarrhoea returned briefly after a later dose increase.
19 Oct 2026Tom, 38 - no city, used metformin alongside another diabetes treatment. He felt more confident after learning to recognise sweating and shaking as possible signs of low blood glucose from the combination rather than from metformin alone. His main complaint was remembering doses when work shifts changed.
25 Oct 2026Liam K., 36 - no city, had taken metformin for more than a year and later reported tingling in his feet and persistent tiredness. Testing showed that vitamin B12 needed attention. He found the follow-up useful, though he wished the possibility had been discussed earlier.
More than a year 8 Nov 2026
